At the time of writing, Abeona Therapeutics Inc [ABEO] stock is trading at $7.93, up 2.19%. An important factor to consider is whether the stock is rising or falling in short-term value. The ABEO shares have gain 7.74% over the last week, with a monthly amount glided 13.45%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Abeona Therapeutics Inc [NASDAQ: ABEO] stock has seen the most recent analyst activity on November 11, 2020, when Cantor Fitzgerald upgraded its rating to a Overweight but kept the price target unchanged to $4 for it. Previously, B. Riley FBR started tracking the stock with Buy rating on September 18, 2020, and set its price target to $5. On February 10, 2020, SVB Leerink initiated with a Outperform rating and assigned a price target of $6 on the stock. Maxim Group downgraded its rating to a Hold. Cantor Fitzgerald downgraded its rating to Neutral for this stock on August 12, 2019, and downed its price target to $2. In a note dated July 26, 2019, Mizuho downgraded an Neutral rating on this stock and revised its target price from $17 to $4.
For the past year, the stock price of Abeona Therapeutics Inc fluctuated between $2.77 and $9.01. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Abeona Therapeutics Inc [NASDAQ: ABEO] shares were valued at $7.93 at the most recent close of the market. An investor can expect a potential drop of -24.34% based on the average ABEO price forecast.
Analyzing the ABEO fundamentals
According to Abeona Therapeutics Inc [NASDAQ:ABEO], the company’s sales were 3.50M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at 0.09% with Operating Profit Margin at -13.77%, Pretax Profit Margin comes in at -15.48%, and Net Profit Margin reading is -15.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.85, Equity is -3.34 and Total Capital is -0.95. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.62 points at the first support level, and at 7.32 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.34, and for the 2nd resistance point, it is at 8.76.
Ratios To Look Out For
It is important to note that Abeona Therapeutics Inc [NASDAQ:ABEO] has a current ratio of 4.15. On the other hand, the Quick Ratio is 4.15, and the Cash Ratio is 1.1. Considering the valuation of this stock, the price to sales ratio is 61.99, the price to book ratio is 14.19.
Transactions by insiders
Recent insider trading involved Seshadri Vishwas, Chief Executive Officer, that happened on Feb 06 ’24 when 20000.0 shares were purchased. Director, Alvino Mark completed a deal on Jan 17 ’24 to sell 7084.0 shares. Meanwhile, Chief Executive Officer Seshadri Vishwas bought 20000.0 shares on Sep 27 ’23.
